Distinct acute lymphoblastic leukemia (ALL)-associated Janus Kinase 3 (JAK3) mutants exhibit different cytokine-receptor requirements and JAK inhibitor specificities

Journal of Biological Chemistry

Volumn 290, Issue 48, 2015, Pages 29022-29034

  Losdyck, Elisabeth ^a,b   Hornakova, Tekla ^a,b   Springuel, Lorraine ^a,b   Degryse, Sandrine ^c   Gielen, Olga ^c   Cools, Jan ^c   Constantinescu, Stefan N ^a,b   Flex, Elisabetta ^d   Tartaglia, Marco ^f   Renauld, Jean Christophe ^a,b   Knoops, Laurent ^a,b,e,g  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^b DE DUVE INSTITUTE   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^f BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^g FNRS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; ENZYMES;

ACUTE LYMPHOBLASTIC LEUKEMIA; CYTOKINE RECEPTOR; DIFFERENT TREATMENTS; JANUS KINASE; SPECIFIC INHIBITORS; TYROSINE KINASE;

DISEASES;

CYTOKINE RECEPTOR; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE 3 INHIBITOR; LEUCINE; RUXOLITINIB; STAT5 PROTEIN; TOFACITINIB; JAK1 PROTEIN, HUMAN; JAK1 PROTEIN, MOUSE; JAK2 PROTEIN, HUMAN; JAK2 PROTEIN, MOUSE; JAK3 PROTEIN, HUMAN; JAK3 PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR; TUMOR PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITOR INTERACTION; GENE MUTATION; GENETIC TRANSDUCTION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMOGENESIS; LYMPHATIC LEUKEMIA; MALE; MOUSE; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; AMINO ACID SUBSTITUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; ENZYMOLOGY; GENETICS; METABOLISM; MISSENSE MUTATION; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TUMOR CELL LINE;

AMINO ACID SUBSTITUTION; ANIMALS; CELL LINE, TUMOR; HUMANS; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; MICE; MICE, INBRED BALB C; MUTATION, MISSENSE; NEOPLASM PROTEINS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; RECEPTORS, CYTOKINE;

EID: 84948452018     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.670224     Document Type: Article

References (33)

1. Haan, C., Rolvering, C., Raulf, F., Kapp, M., Drückes, P., Thoma, G., Behrmann, I., and Zerwes, H. G. (2011) Jak1 has a dominant role over Jak3 in signal transduction through c-containing cytokine receptors. Chem. Biol. 18, 314-323
2. Saharinen, P., and Silvennoinen, O. (2002) The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J. Biol. Chem. 277, 47954-47963
3. Haan, C., Is'harc, H., Hermanns, H. M., Schmitz-Van De Leur, H., Kerr, I. M., Heinrich, P. C., Grötzinger, J., and Behrmann, I. (2001) Mapping of a region within the N terminus of Jak1 involved in cytokine receptor interaction. J. Biol. Chem. 276, 37451-37458
4. Tang, W., Huo, H., Zhu, J., Ji, H., Zou, W., Xu, L., Sun, L., Zheng, Z., Theze, J., and Liu, X. (2001) Critical sites for the interaction between IL-2R- and JAK3 and the following signaling. Biochem. Biophys. Res. Commun. 283, 598-605
5. Cacalano, N. A., Migone, T. S., Bazan, F., Hanson, E. P., Chen, M., Candotti, F., O'Shea, J. J., and Johnston, J. A. (1999) Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain. EMBO J. 18, 1549-1558
6. Bains, T., Heinrich, M. C., Loriaux, M. M., Beadling, C., Nelson, D., Warrick, A., Neff, T. L., Tyner, J. W., Dunlap, J., Corless, C. L., and Fan, G. (2012) Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia. Leukemia 26, 2144-2146
7. Walters, D. K., Mercher, T., Gu, T. L., O'Hare, T., Tyner, J. W., Loriaux, M., Goss, V. L., Lee, K. A., Eide, C. A., Wong, M. J., Stoffregen, E. P., McGreevey, L., Nardone, J., Moore, S. A., Crispino, J., Boggon, T. J., Heinrich, M. C., Deininger, M. W., Polakiewicz, R. D., Gilliland, D. G., and Druker, B. J. (2006) Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 10, 65-75
8. Sakaguchi, H., Okuno, Y., Muramatsu, H., Yoshida, K., Shiraishi, Y., Takahashi, M., Kon, A., Sanada, M., Chiba, K., Tanaka, H., Makishima, H., Wang, X., Xu, Y., Doisaki, S., Hama, A., Nakanishi, K., Takahashi, Y., Yoshida, N., Maciejewski, J. P., Miyano, S., Ogawa, S., and Kojima, S. (2013) Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat. Genet. 45, 937-941
9. Kudlacz, E., Conklyn, M., Andresen, C., Whitney-Pickett, C., and Changelian, P. (2008) The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. Eur. J. Pharmacol 582, 154-161
10. Kudlacz, E., Perry, B., Sawyer, P., Conklyn, M., McCurdy, S., Brissette, W., Flanagan, and Changelian, P. (2004) The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am. J. Transplant 4, 51-57
11. Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., Faraoni, R., Floyd, M., Hunt, J. P., Lockhart, D. J., Milanov, Z. V., Morrison, M. J., Pallares, G., Patel, H. K., Pritchard, S., Wodicka, L. M., and Zarrinkar, P. P. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132
12. Arana Yi, C., Tam, C. S., and Verstovsek, S. (2015) Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis. Future Oncol. 11, 719-733
13. Degryse, S., de Bock, C. E., Cox, L., Demeyer, S., Gielen, O., Mentens, N., Jacobs, K., Geerdens, E., Gianfelici, V., Hulselmans, G., Fiers, M., Aerts, S., Meijerink, J. P., Tousseyn, T., and Cools, J. (2014) JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood 124, 3092-3100
14. Gerland, K., Bataillé-Simoneau, N., Baslé, M., Fourcin, M., Gascan, H., and Mercier, L. (2000) Activation of the Jak/Stat signal transduction pathway in GH-treated rat osteoblast-like cells in culture. Mol. Cell. Endocrinol. 168, 1-9
15. Dumoutier, L., Louahed, J., and Renauld, J. C. (2000) Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J. Immunol. 164, 1814-1819
16. Springuel, L., Hornakova, T., Losdyck, E., Lambert, F., Leroy, E., Constantinescu, S. N., Flex, E., Tartaglia, M., Knoops, L., and Renauld, J. C. (2014) Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors. Blood 124, 3924-3931
17. Thoma, G., Nuninger, F., Falchetto, R., Hermes, E., Tavares, G. A., Vangrevelinghe, E., and Zerwes, H. G. (2011) Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family. J. Med. Chem. 54, 284-288
18. Yamashita, Y., Yuan, J., Suetake, I., Suzuki, H., Ishikawa, Y., Choi, Y. L., Ueno, T., Soda, M., Hamada, T., Haruta, H., Takada, S., Miyazaki, Y., Kiyoi, H., Ito, E., Naoe, T., Tomonaga, M., Toyota, M., Tajima, S., Iwama, A., and Mano, H. (2010) Array-based genomic resequencing of human leukemia. Oncogene 29, 3723-3731
19. Riera, L., Lasorsa, E., Bonello, L., Sismondi, F., Tondat, F., Di Bello, C., Di Celle, P. F., Chiarle, R., Godio, L., Pich, A., Facchetti, F., Ponzoni, M., Marmont, F., Zanon, C., Bardelli, A., and Inghirami, G. (2011) Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects. Leukemia Lymphoma 52, 1742-1750
20. Lu, X., Levine, R., Tong, W., Wernig, G., Pikman, Y., Zarnegar, S., Gilliland, D. G., and Lodish, H. (2005) Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc. Natl. Acad. Sci. U.S.A. 102, 18962-18967
21. Hornakova, T., Staerk, J., Royer, Y., Flex, E., Tartaglia, M., Constantinescu, S. N., Knoops, L., and Renauld, J. C. (2009) Acute lymphoblastic leukemiaassociated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers. J. Biol. Chem. 284, 6773-6781
22. Malka, Y., Hornakova, T., Royer, Y., Knoops, L., Renauld, J. C., Constantinescu, S. N., and Henis, Y. I. (2008) Ligand-independent homomeric and heteromeric complexes between interleukin-2 or-9 receptor subunits and the - chain. J. Biol. Chem. 283, 33569-33577
23. Wernig, G., Gonneville, J. R., Crowley, B. J., Rodrigues, M. S., Reddy, M. M., Hudon, H. E., Walz, C., Reiter, A., Podar, K., Royer, Y., Constantinescu, S. N., Tomasson, M. H., Griffin, J. D., Gilliland, D. G., and Sattler, M. (2008) The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood 111, 3751-3759
24. Bellanger, D., Jacquemin, V., Chopin, M., Pierron, G., Bernard, O. A., Ghysdael, J., and Stern, M. H. (2014) Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia. Leukemia 28, 417-419
25. Hornakova, T., Springuel, L., Devreux, J., Dusa, A., Constantinescu, S. N., Knoops, L., and Renauld, J. C. (2011) Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. Haematologica 96, 845-853
26. Gordon, G. M., Lambert, Q. T., Daniel, K. G., and Reuther, G. W. (2010) Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon. Biochem. J. 432, 255-265
27. He, M., Capelletti, M., Nafa, K., Yun, C. H., Arcila, M. E., Miller, V. A., Ginsberg, M. S., Zhao, B., Kris, M. G., Eck, M. J., Jänne, P. A., Ladanyi, M., and Oxnard, G. R. (2012) EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin. Cancer Res. 18, 1790-1797
28. Yamaguchi, F., Kugawa, S., Tateno, H., Kokubu, F., and Fukuchi, K. (2012) Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy. Lung Cancer 78, 201-206
29. Yamaguchi, F., Fukuchi, K., Yamazaki, Y., Takayasu, H., Tazawa, S., Tateno, H., Kato, E., Wakabayashi, A., Fujimori, M., Iwasaki, T., Hayashi, M., Tsuchiya, Y., Yamashita, J., Takeda, N., and Kokubu, F. (2014) Acquired resistance L747S mutation in an epidermal growth factor receptor-tyrosine kinase inhibitor-naive patient: A report of three cases. Oncol. Lett. 7, 357-360
30. Huse, M., and Kuriyan, J. (2002) The conformational plasticity of protein kinases. Cell 109, 275-282
31. Zhou, Y. J., Chen, M., Cusack, N. A., Kimmel, L. H., Magnuson, K. S., Boyd, J. G., Lin, W., Roberts, J. L., Lengi, A., Buckley, R. H., Geahlen, R. L., Candotti, F., Gadina, M., Changelian, P. S., and O'Shea, J. J. (2001) Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. Mol. Cell 8, 959-969
32. Lupardus, P. J., Skiniotis, G., Rice, A. J., Thomas, C., Fischer, S., Walz, T., and Garcia, K. C. (2011) Structural snapshots of full-length Jak1, a transmembrane gp130/IL-6/IL-6Ralpha cytokine receptor complex, and the receptor-Jak1 holocomplex. Structure 19, 45-55
33. Lupardus, P. J., Ultsch, M., Wallweber, H., Bir Kohli, P., Johnson, A. R., and Eigenbrot, C. (2014) Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Proc. Natl. Acad. Sci. U.S.A. 111, 8025-8030